Dae Jung Kim – President, Daiichi Sankyo Korea
Dae Jung Kim, president of Daiichi Sankyo Korea provides an insight into the rationale behind the company’s focus on the cardiovascular therapeutic area in South Korea. Mr Kim also reveals…
Bioneer Corp., founded in 1992 as the first bio-venture in South Korea, is moving forward to a full-fledged molecular biotechnology company on the strength of the R&D infrastructure and intellectual properties.
Since beginning the home production of synthetic oligonucleotides and PCR enzymes with its proprietary technology for the first time in Korea, Bioneer has continuously built up expertise in molecular diagnostics and RNAi therapeutics. Bioneer is currently providing total solutions for molecular diagnostics in various disease areas through an integrated platform of reagents, instruments and analysis software. Bioneer’s SAMiRNA™ is a new paradigm of RNAi therapeutics in terms of being a much more efficient carrier compared to the conventional methods to deliver siRNA to the inside of a target cell.
Bioneer has vertically integrated genomic technology-based businesses, which provides competitive advantages in the market such as price competitiveness, product development efficiency and a high level of control. Today, Bioneer is operating businesses in the following three domains: Research-use products in genomics, biotechnology, molecular biology, etc.; Molecular diagnostic reagents, instruments and software; New development based on RNAi.
Contact details
Webpage: www.bioneer.com
Address: 8-11, Munpyeongseo-ro, Daedeok-gu, Daejeon 306-220, Republic of Korea
Tel: +82-42-930-8777
Fax: +82-42-930-8688
Email: sales@bioneer.com
Dae Jung Kim, president of Daiichi Sankyo Korea provides an insight into the rationale behind the company’s focus on the cardiovascular therapeutic area in South Korea. Mr Kim also reveals…
Kyung Kook Lee, chairman of KMDIA, explains the association’s role in working with the medical devices industry to boost both the local market and to raise Korea’s profile as a…
Jung Hyun Yun lifts the lid on Biosolution’s new stem cell technology that could revolutionize the treatment of cartilage-related ailments, such as osteoarthritis. He also discusses the plans for global…
Antimicrobial resistance (AMR) is a global health concern that we are increasingly understanding the consequences of and pulling together to try and keep under control. Korea is one of the…
Paul Henry Huibers, president of Lilly Korea discusses Lilly’s strong double-digit growth following a challenging period of restructuring. Huibers offers his opinion on the pricing difficulties within the Korean market,…
The South Korean government has designated the promotion of artificial intelligence (AI)-based drug development and healthcare innovation as a national priority. This new policy aims to capitalise on Korea’s advanced…
Uloff Münster, general manager of Merck Biopharma Korea provides his insights into the Korean healthcare system. Dr Münster also discusses the drug pricing situation in Korea and the potential for…
Young Jack Lee, CEO of LSK Global PS, Korea’s largest local contract research organization (CRO) gives his insights on the evolution of the clinical research environment over the past four…
Yong-Ik Kim, president of Korea’s National Health Insurance Service (NHIS), provides an insight into the implementation of the upcoming MoonCare reforms, the government’s strategy to ensure the expansion of coverage…
Kyungjin Peter Kim, CEO of ST Pharm, provides an insight into his expansion of the company’s operations from simply a CMO into a CDMO and new drug development. He also…
Sean Kim, senior director at the Korea Research-Based Pharma Industry Association (KRPIA) gives his assessment of the role of MNCs within the pharma industry in South Korea. At the…
Roger Zbinden, head of the Swiss Business Hub Korea, explains their efforts to raise the profile of the South Korean market for Swiss business. Dr Zbinden also provides his insights…
See our Cookie Privacy Policy Here
